Applying mixture toxicity modelling to predict bacterial bioluminescence inhibition by non-specifically acting pharmaceuticals and specifically acting antibiotics

Peta A. Neale^{a,b}, Frederic D.L. Leusch^{a*}, Beate I. Escher^{b,c,d}

^aAustralian Rivers Institute, Griffith School of Environment, Griffith University, Southport, QLD 4222, Australia

^bThe University of Queensland, National Research Centre for Environmental Toxicology (Entox), Brisbane, QLD 4108, Australia

^cUFZ – Helmholtz Centre for Environmental Research, Cell Toxicology, 04318 Leipzig, Germany

^dEberhard Karls University Tübingen, Environmental Toxicology, Center for Applied Geoscience, 72074 Tübingen, Germany

*Corresponding author: f.leusch@griffith.edu.au; Ph: +61 7 5552 7832

36 **Abstract**

37 Pharmaceuticals and antibiotics co-occur in the aquatic environment but mixture studies to date
38 have mainly focused on pharmaceuticals alone or antibiotics alone, although differences in mode of
39 action may lead to different effects in mixtures. In this study we used the Bacterial Luminescence
40 Toxicity Screen (BLT-Screen) after acute (0.5 h) and chronic (16 h) exposure to evaluate how non-
41 specifically acting pharmaceuticals and specifically acting antibiotics act together in mixtures.
42 Three models were applied to predict mixture toxicity including concentration addition,
43 independent action and the two-step prediction (TSP) model, which groups similarly acting
44 chemicals together using concentration addition, followed by independent action to combine the
45 two groups. All non-antibiotic pharmaceuticals had similar EC_{50} values at both 0.5 and 16 h,
46 indicating together with a QSAR (Quantitative Structure-Activity Relationship) analysis that they
47 act as baseline toxicants. In contrast, the antibiotics' EC_{50} values decreased by up to three orders of
48 magnitude after 16 h, which can be explained by their specific effect on bacteria. Equipotent
49 mixtures of non-antibiotic pharmaceuticals only, antibiotics only and both non-antibiotic
50 pharmaceuticals and antibiotics were prepared based on the single chemical results. The mixture
51 toxicity models were all in close agreement with the experimental results, with predicted EC_{50}
52 values within a factor of two of the experimental results. This suggests that concentration addition
53 can be applied to bacterial assays to model the mixture effects of environmental samples containing
54 both specifically and non-specifically acting chemicals.

55
56 **Keywords:** antibiotics; bacterial toxicity; concentration addition; independent action;
57 pharmaceuticals

58

59

60 1. Introduction

61 Bacterial assays based on bioluminescence inhibition are widely applied tools to evaluate the effect
62 of individual chemicals, chemical mixtures and environmental samples (Altenburger et al., 2000;
63 Katsoyiannis and Samara, 2007; Escher et al., 2008; Tang et al., 2013). The advantages of such
64 assays include ease of use, sensitivity and speed, with sample exposure times typically between 15
65 to 30 minutes (Parvez et al., 2006). Further, Kaiser (1998) found a good correlation between a range
66 of aquatic *in vivo* endpoints and observed effect in marine bacteria *Aliivibrio fischeri*, more
67 commonly referred to as the Microtox assay. While acute bacterial assays are suitable for non-
68 specifically acting compounds, their applicability to specifically acting chemicals, such as
69 antibiotics, is questionable, with several studies finding low or no effect in the Microtox assay after
70 exposure to different classes of antibiotics (Isidori et al., 2005; van der Grinten et al., 2010).
71 Antibiotics can have specific effects on different bacterial species, including inhibition of protein
72 synthesis and inhibition of DNA synthesis (Kohanski et al., 2010), thus the typical short exposure
73 times are not sufficient to account for the specific effects of antibiotics. Consequently, previous
74 studies have shown that antibiotic effects in bacterial assays can increase by several orders of
75 magnitude with longer exposure periods (Thomulka et al., 1993; Backhaus et al., 1997; Froehner et
76 al., 2000; Zou et al., 2012).

77
78 While there are increasing concerns about the presence of antibiotics in the aquatic environment
79 (Kummerer, 2009), environmental waters can contain a wide range of chemicals, including
80 pharmaceuticals, pesticides and industrial compounds (Loos et al., 2013; Neale et al., 2015).
81 Consequently, it is important to consider the potential mixture effects that can occur between
82 chemicals. Mixtures that contain chemicals that share a common mode of action in a particular
83 organism can be predicted using the concentration addition model, while chemicals that act
84 according to different modes of action can be described by independent action (Backhaus and Faust,
85 2012). While environmental samples typically contain a large number of chemicals with diverse
86 modes of action, the concentration addition model is considered to be suitable for hazard
87 assessment as it provides a worst-case prediction of mixture toxicity in most cases (Backhaus et al.,
88 2000). An alternative approach is the two-step prediction (TSP) model proposed by Junghans
89 (2004), which groups similarly acting compounds together using the concentration addition model
90 and then applies independent action to combine the predicted effects of the individual groups. This
91 has previously been applied to successfully predict mixture toxicity in *Daphnia magna* (Ra et al.,
92 2006) and algal assays (Tang and Escher, 2014).

93

94 In this study the Bacterial Luminescence Toxicity Screen (BLT-Screen) using bioluminescent
95 bacteria *Photobacterium leiognathi* was applied to single compounds and mixtures containing both
96 non-specifically acting pharmaceuticals, referred to as non-antibiotic pharmaceuticals, and
97 specifically acting antibiotics after both acute and chronic exposure. Backhaus et al. (1997) showed
98 that the ratio of acute to chronic effects in bioluminescent bacteria can provide information about
99 the mode of action of studied chemicals, with an increased acute to chronic ratio observed for
100 specifically acting chemicals. In the current study 0.5 h was used for acute exposure as this is the
101 typical sample exposure period in the assay (van de Merwe and Leusch, 2015), while 16 h was used
102 for chronic exposure. The studied compounds have all been detected previously in wastewater and
103 surface water in the ng/L to µg/L concentration range (Kolpin et al., 2002; Watkinson et al., 2009;
104 Hughes et al., 2013; Loos et al., 2013). Effect concentrations inhibiting 50% of the bioluminescence
105 output (EC₅₀) were determined at both 0.5 and 16 h for individual compounds, with equipotent
106 mixtures of non-antibiotic pharmaceuticals only, antibiotics only and both non-antibiotic
107 pharmaceuticals and antibiotics prepared based on the ratio of the experimental EC₅₀ values. The
108 observed effects were compared with predicted effects based on the concentration addition,
109 independent action and TSP models.

110

111 **2. Materials and methods**

112 *2.1 Chemicals*

113 Five non-antibiotic pharmaceuticals, carbamazepine, diclofenac, fluoxetine, gemfibrozil and
114 naproxen, and five antibiotics, doxycycline, monensin, sulfamethizole, sulfamethoxazole and
115 tetracycline, were selected for this study. Properties of the studied chemicals are provided in Table
116 1. Pentachlorophenol (PCP) was used as the positive reference compound for the BLT-Screen. PCP
117 is an weak acid uncoupler and exhibits a specific effect in the assay (Schultz and Cronin, 1997).
118 Individual chemical stocks and chemical mixtures were prepared in HPLC grade methanol. All
119 chemicals were purchased from Sigma Aldrich (Castle Hill, Australia) or Novachem Pty Ltd
120 (Collingwood, Australia).

121

122 *2.2 Bioanalysis*

123 The BLT-Screen was run according to van de Merwe and Leusch (2015), with some modifications.
124 Briefly, the chemical stocks, along with positive control PCP and solvent control methanol, were
125 added to white 96 well plates and serially diluted in phosphate buffer (pH 4) using either a 1:3 or
126 1:5 dilution series, with a final volume of 200 µL. The final concentration of methanol in the assay
127 did not exceed 0.8% (v/v). While many bacterial assays are conducted at pH 7, the BLT-Screen was
128 run at pH 4 to increase assay sensitivity to organic contaminants (van de Merwe and Leusch, 2015).

129 Following the serial dilution, a cryopreserved *Photobacterium leiognathi* stock was thawed and
 130 diluted 1:6 in growth medium, with 5 µL of growth medium added to each well. Luminescence was
 131 measured at 0.5 and 16 h using a Fluostar Omega plate reader (BMG Labtech, Ortenberg,
 132 Germany). Between readings, the plates were stored at 22°C and gently shaken at 90 RPM. Percent
 133 luminescence inhibition was calculated using Equation 1 based on sample luminescence, provided
 134 in relative light units (RLU), (RLU_{sample}) and the average luminescence of the solvent control
 135 (RLU_{control}). All samples were run in duplicate on the same plate, with each sample run
 136 independently two to three times. RLU_{control} was reasonably stable between experiments (coefficient
 137 of variance <20%), with RLU_{control} typically decreasing by approximately 35% from 0.5 to 16 h.
 138 The effect concentration causing 50% effect (EC₅₀) at 0.5 and 16 h was calculated using log-logistic
 139 concentration-effect curves (Equation 2), where EC_i is the concentration at a defined percent effect
 140 y. The slope was fitted from the experimental data.

$$\% \text{ Inhibition} = \left(1 - \frac{\text{RLU}_{\text{sample}}}{\text{RLU}_{\text{control}}}\right) \cdot 100\%$$

(1)

$$\% \text{ effect (y)} = \frac{1}{1 + 10^{\text{slope} \cdot (\log \text{EC}_{50} - \log \text{EC}_i)}}$$

(2)

144 2.3 Mixture toxicity modelling

145 Using the experimental EC₅₀ values for the individual chemicals, equipotent mixtures were
 146 prepared for non-antibiotic pharmaceuticals only (5 components), antibiotics only (5 components)
 147 and all chemicals (10 components) for both 0.5 and 16 h time points. All components contribute
 148 equally to the mixture effect in equipotent mixtures and the fraction of each chemical included in
 149 the mixtures is provided in Table 2. The experimental results were compared with concentration
 150 addition, independent action and TSP mixture toxicity predictions. EC₅₀ based on the concentration
 151 addition predictions (EC_{50,CA}) was calculated using Equation 3, where p_i is the fraction of
 152 component i (i = 1 to n) in the mixture and EC_{y,i} is the EC_y of component i at any effect level y. As
 153 standard error is symmetrical on a log scale, Equation 3 was expanded to Equation 4 to calculate log
 154 EC_{y,CA}. The effect predicted based on independent action (E_{IA}) was determined using Equation 5,
 155 where E_i is the effect of component i in the mixture.

$$\text{EC}_{y,CA} = \frac{1}{\sum_{i=1}^n \frac{p_i}{\text{EC}_{y,i}}}$$

(3)

$$\log EC_{y,CA} = \log \left(\left(\frac{p_1}{EC_{y,1}} \right) + \left(\frac{p_2}{EC_{y,2}} \right) + \left(\frac{p_3}{EC_{y,3}} \right) + \dots \right) \quad (4)$$

$$E_{IA} = 1 - \prod_{i=1}^n (1 - E_i) \quad (5)$$

The variability associated with the mixture toxicity model predictions was estimated using error propagation. For concentration addition, Equation 2 was rearranged to give Equation 6, with the error associated with $\log EC_{y,i}$, $\sigma \log EC_{y,i}$, calculated for each component i using Equation 7.

$$\log EC_{y,i} = \log EC_{50,i} - \frac{1}{\text{slope}} \cdot \log \left(\frac{1-y}{y} \right) \quad (6)$$

$$\sigma \log EC_{y,i} = \sqrt{\sigma \log EC_{50,i}^2 + \left(\log \frac{1-y}{y} \right)^2 \cdot \left(\frac{\sigma \text{slope}}{\text{slope}^2} \right)^4} \quad (7)$$

The error associated with the concentration addition prediction, $\sigma \log EC_{y,CA}$, was estimated using Equation 8, with $\frac{d \log EC_{y,CA}}{d \log EC_{y,i}}$ calculated using Equation 9.

$$\sigma \log EC_{y,CA} = \sqrt{\sum_{i=1}^n \left(\frac{d \log EC_{y,CA}}{d \log EC_{y,i}} \right)^2 \cdot \sigma \log EC_{y,i}^2} \quad (8)$$

$$\frac{d \log EC_{y,CA}}{d \log EC_{y,i}} = \frac{p_1 \cdot 10^{-\log EC_{y,1}}}{p_1 \cdot 10^{-\log EC_{y,1}} + p_2 \cdot 10^{-\log EC_{y,2}} + p_3 \cdot 10^{-\log EC_{y,3}} + \dots} \quad (9)$$

For independent action, the error associated with effect _{i} , σeffect_i , was calculated for each component i using Equation 10. The required parameters for Equation 10 were calculated using Equations 11 to 13, where C is the concentration and $\ln$ is the natural logarithm.

$$\sigma E_i = \sqrt{\left(\frac{dE_i}{dslope_i}\right)^2 \cdot \sigma slope_i^2 + \left(\frac{dE_i}{d\log EC_{50,i}}\right)^2 \cdot \sigma \log EC_{50,i}^2 + \left(\frac{dE_i}{d\log C}\right)^2 \cdot \sigma \log C^2}$$

$$\frac{dE_i}{dslope_i} = \frac{10^{slope \cdot (\log EC_{50,i} - \log C)} \cdot (\log EC_{50,i} - \log C) \cdot \ln 10}{(1 + 10^{slope \cdot (\log EC_{50,i} - \log C)})^2}$$

$$\frac{dE_i}{d\log EC_{50,i}} = \frac{10^{slope \cdot (\log EC_{50,i} - \log C)} \cdot slope \cdot \ln 10}{(1 + 10^{slope \cdot (\log EC_{50,i} - \log C)})^2}$$

$$\frac{dE_i}{d\log C} = \frac{10^{slope \cdot (\log EC_{50,i} - \log C)} \cdot slope \cdot \ln 10}{(1 + 10^{slope \cdot (\log EC_{50,i} - \log C)})^2}$$

The error associated with the independent action predicted effect, σE_{IA} , was calculated with Equation 14 for $i = 1, 2, 3$ and can be expanded to the required number of i .

$$\sigma E_{IA} = \sqrt{((1-E_2) \cdot (1-E_3) \cdot \sigma E_1)^2 + ((1-E_1) \cdot (1-E_3) \cdot \sigma E_2)^2 + ((1-E_1) \cdot (1-E_2) \cdot \sigma E_3)^2}$$

The CA prediction was calculated for a range of effect levels y to draw a complete concentration-effect curve for CA, while the IA prediction was calculated for a range of concentrations C to draw a complete concentration-effect curve for IA. For the ten-component mixtures, the TSP model was also applied by predicting concentration addition for the non-antibiotic pharmaceutical group and antibiotics group separately and then combining the two groups together using the independent action model.

3. Results and discussion

3.1 Individual chemicals

The EC_{50} values at 0.5 and 16 h are provided for all individual chemicals in Table 3, with the full concentration-effect curves shown in Figure 1. There was little change in EC_{50} over time for the studied non-antibiotic pharmaceuticals, with the ratio of EC_{50} at 0.5 h to EC_{50} at 16 h ranging from 1.0 to 4.4 (Table 3). This is also shown in Figure 2, where the difference in $\log EC_{50}$ for all non-

antibiotic pharmaceuticals at 0.5 and 16 h falls within 0.5 log units. As the effect remained relatively constant over time, this indicates that the studied non-antibiotic pharmaceuticals were baseline toxicants and did not exhibit a specific effect on *Photobacterium leiognathi*. In contrast, the effect of the antibiotics increased with time, with the EC₅₀ values decreasing by up to three orders of magnitude (Table 3). The ratio of EC₅₀ at 0.5 h to EC₅₀ at 16 h ranged from 7.2 to 995. The two most potent antibiotics, doxycycline and tetracycline, inhibit protein synthesis, and previous studies also found that this class of antibiotics were among the most toxic to *Aliivibrio fischeri* (Backhaus and Grimme, 1999). In contrast, the sulphonamides, sulfamethoxazole and sulfamethizole, which are inhibitors of folic acid, had the lowest decrease in EC₅₀ values over time. This has been observed previously (Zou et al., 2012) and it has been hypothesised that the presence of bacteria growth media components, such as yeast extract, may be a source of folic acid for the bacteria (Backhaus and Grimme, 1999). Yeast extract is composed of autolyzed *Saccharomyces cerevisiae* cells, with *Saccharomyces cerevisiae* strains previously shown to contain total folate concentrations ranging from 4 to 14.5 mg per 100 g of dried yeast extract (Hjortmo et al., 2005). The growth media contained 3 g/L of yeast extract (van de Merwe and Leusch, 2015), with 5 µL of growth media added to 200 µL sample volume in the BLT-Screen giving a final volume of 205 µL, thus the potential concentration of folate in the assay was 2.9 to 10.6 µg/L.

The results were compared with the baseline toxicity Quantitative Structure-Activity Relationship (QSAR) developed by Tang et al. (2013) for the Microtox assay based on 0.5 h exposure. The QSAR was developed based on the liposome-water partition coefficient (K_{lipw}) of neutral chemicals, but was shown to be applicable to ionisable organic chemicals when K_{lipw} was replaced with the speciation-corrected distribution ratio (D_{lipw}) (Tang et al., 2013). While octanol-water partition coefficients (K_{ow}) are often used for QSARs, previous studies have shown that liposome-water partition coefficients (K_{lipw}) are a suitable descriptor for both polar and nonpolar chemicals (Vaes et al., 1997) and have been successfully applied to predict toxicity using QSAR models (Tang et al., 2013; Klüver et al., 2016). As many of the studied chemicals are charged at pH 4, D_{lipw} was used in the QSAR to account for speciation (Table 1). Therefore, while the QSAR was developed based on the experimental K_{lipw} of neutral compounds, D_{lipw} could be applied to correct for speciation at pH 4. Figure 3 indicates that the majority of non-antibiotic pharmaceuticals fit well with the QSAR predictions based on the Microtox assay, with the ratio of the QSAR predicted EC₅₀ to the experimental EC₅₀, also known as the toxic ratio, less than 10, suggesting that the non-antibiotic pharmaceuticals are baseline toxicants (Tang et al., 2013). The exception was naproxen, which had a toxic ratio from 70 (0.5 h) to 250 (16 h). While a toxic ratio above 10 usually indicates that a compound has a specific mode of action, the acute to chronic ratio for naproxen was 3.6, which

suggests that it is having a non-specific effect on *Photobacterium leiognathi*. Thus, the dissimilarity may be related to differences in sensitivity of the applied bacterial strain (*Aliivibrio fischeri* compared to *Photobacterium leiognathi*). van de Merwe and Leusch (2015) also found a similar EC₅₀ value for naproxen in the BLT-Screen (Figure 3). In contrast, all antibiotics at both 0.5 and 16 h deviated significantly from the baseline toxicity QSAR, which was also observed by Tang et al. (2013).

3.2 Mixture toxicity modelling

Experimental EC₅₀ values for the separate equipotent non-antibiotic pharmaceutical and antibiotics mixtures were compared with EC₅₀ values predicted using concentration addition and independent action (Table 4). Concentration addition was more conservative than independent action for the non-antibiotic pharmaceutical-only mixtures at both 0.5 and 16 h, with the concentration addition predicted concentration-effect curves agreeing well with the experimental results (Figure 4A-B). However, the independent action EC₅₀ predictions were only a factor of two higher than the experimental EC₅₀ values. For the antibiotics, independent action yielded a lower EC₅₀ at 0.5 h (Figure 4C), while both concentration addition and independent action provided close agreement with the experimental EC₅₀ value at 16 h (Figure 4D). The suitability of the independent action model at 16 h may be due to the fact that the different antibiotics have different modes of action on bacteria, such as protein synthesis inhibition and folic acid inhibition, which is not apparent after only 0.5 h exposure (Froehner et al., 2000). Independent action was also shown to be the most applicable model to predict mixture toxicity of dissimilarly acting compounds using *Aliivibrio fischeri* (Backhaus et al., 2000). However, concentration addition was overall the most suitable model for the five-component mixtures, with predictions within a factor of 1.1 to 1.4 of the experimental results, meaning it is suitable for use in the TSP model.

The effect of the ten-component mixture containing both non-antibiotic pharmaceuticals and antibiotics was predicted using concentration addition, independent action and the TSP model (Table 4, Figure 4E-F). For the TSP model, the concentration addition predictions of the five-component mixtures of either non-antibiotic pharmaceuticals or antibiotics were integrated using independent action, with p_i representing the fraction of each group in the ten-component mixture. This was possible as the ratio of similarly acting components within each group remained the same in both the five and ten-component mixtures. All three models gave a good agreement with the experimental data, with all predictions within a factor of two of the experimental EC₅₀ values. The TSP model tended to fall between the concentration addition and independent action predictions, indicating that the TSP model is an appropriate model to predict the effect of specific and non-

specific chemicals in bioluminescent bacterial assays. However, given the similarity of all predictions, this still supports the application of concentration addition as a suitable model for compounds whose mode of action is unknown, given it tends to be more conservative, particularly at the chronic 16 h exposure. This suggests that the bioanalytical equivalent approach, which assumes that chemicals act according to concentration addition (Neale et al., 2015), can be applied to predict the mixture toxicity of environmental samples containing both antibiotics and non-specifically acting chemicals in bacterial assays.

4. Conclusions

In this study the effect of two groups of commonly detected water pollutants, pharmaceuticals and antibiotics, were assessed in the BLT-Screen after acute (0.5 h) and chronic (16 h) exposure periods, with equipotent mixtures prepared. Despite using a different bacterial species, the EC₅₀ values for most non-antibiotic pharmaceuticals fit well with previously published baseline toxicity QSAR predictions; however, the QSAR was clearly unsuitable for specifically acting antibiotics, with the observed effect two to seven orders of magnitude higher than predicted. Thus, while the bioluminescence inhibition of bacteria is widely applied to test the baseline toxicity of chemical and environmental mixtures (Altenburger et al., 2000; Tang et al., 2013; Di Nica et al., 2016; Vethaak et al., 2016), antibiotics appear to be outliers. The applied mixture toxicity models of concentration addition, independent action and TSP all gave a good agreement with the experimental data. While independent action and TSP may have given closer predictions, concentration addition is still recommended for mixture toxicity modelling of dissimilarly acting compounds. Therefore, it is still possible to apply this assay to environmental mixtures, such as water samples, even if they contain substantial fractions of antibiotics because the overall mixture effect can be satisfactorily modelled by concentration addition.

Acknowledgments

This study was supported by the National Health and Medical Research Council (NHMRC) – European Union Collaborative Research Grant (APP1074775) and is part of the SOLUTIONS project, which is supported by the European Union Seventh Framework Programme. Maud Achard and Emma Parsons, Griffith University, are thanked for experimental assistance and Jason van de Merwe, Griffith University, and Martin Scholze, Brunel University, are thanked for useful discussions.

307 **References**

- 308 Altenburger, R., Backhaus, T., Boedeker, W., Faust, M., Scholze, M., Grimme, L.H., 2000.
309 Predictability of the toxicity of multiple chemical mixtures to *Vibrio fischeri*: Mixtures composed of
310 similarly acting chemicals. Environ. Toxicol. Chem. 19, 2341-2347.
- 311 Avdeef, A., Box, K.J., Comer, J.E.A., Hibbert, C., Tam, K.Y., 1998. pH-metric logP 10.
312 Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm. Res.
313 15, 209-215.
- 314 Backhaus, T., Altenburger, R., Boedeker, W., Faust, M., Scholze, M., Grimme, L.H., 2000.
315 Predictability of the toxicity of a multiple mixture of dissimilarly acting chemicals to *Vibrio*
316 *fischeri*. Environ. Toxicol. Chem. 19, 2348-2356.
- 317 Backhaus, T., Faust, M., 2012. Predictive environmental risk assessment of chemical mixtures: A
318 conceptual framework. Environ. Sci. Technol. 46, 2564-2573.
- 319 Backhaus, T., Froehner, K., Altenburger, R., Grimme, L.H., 1997. Toxicity testing with *Vibrio*
320 *fischeri*: A comparison between the long term (24 h) and the short term (30 min) bioassay.
321 Chemosphere 35, 2925-2938.
- 322 Backhaus, T., Grimme, L.H., 1999. The toxicity of antibiotic agents to the luminescent bacterium
323 *Vibrio fischeri*. Chemosphere 38, 3291-3301.
- 324 Di Nica, V., Villa, S., Finizio, A., 2016. Toxicity of individual pharmaceuticals and their mixtures
325 to *Aliivibrio fischeri*: Experimental results for single compounds, consideration of their mechanisms
326 of action and potential acute effects on aquatic organisms. Environ. Toxicol. Chem. In Press DOI
327 10.1002/etc.3568.
- 328 Escher, B.I., Baumgartner, R., Koller, M., Treyer, K., Lienert, J., McArdell, C.S., 2011.
329 Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water
330 Res. 45, 75-92.
- 331 Escher, B.I., Bramaz, N., Mueller, J.F., Quayle, P., Rutishauser, S., Vermeirssen, E.L.M., 2008.
332 Toxic equivalent concentrations (TEQs) for baseline toxicity and specific modes of action as a tool
333 to improve interpretation of ecotoxicity testing of environmental samples. J. Environ. Monitor. 10,
334 612-621.
- 335 Froehner, K., Backhaus, T., Grimme, L.H., 2000. Bioassays with *Vibrio fischeri* for the assessment
336 of delayed toxicity. Chemosphere 40, 821-828.

337 Hjortmo, S., Patring, J., Jastrebova, J., Andlid, T., 2005. Inherent biodiversity of folate content and
338 composition in yeasts. Trends Food Sci. Technol. 16, 311-316.

339 Hughes, S.R., Kay, P., Brown, L.E., 2013. Global synthesis and critical evaluation of
340 pharmaceutical data sets collected from river systems. Environ. Sci. Technol. 47, 661-677.

341 Isidori, M., Lavorgna, M., Nardelli, A., Pascarella, L., Parrella, A., 2005. Toxic and genotoxic
342 evaluation of six antibiotics on non-target organisms. Sci. Total Environ, 346, 87-98.

343 Junghans, M., 2004. Studies on combination effects of environmentally relevant toxicants:
344 Validation of prognostic concepts for assessing the algal toxicity of realistic aquatic pesticide
345 mixtures, PhD Thesis. University of Bremen, Bremen, Germany.

346 Kaiser, K.L.E., 1998. Correlations of *Vibrio fischeri* bacteria test data with bioassay data for other
347 organisms. Environ. Health Perspect. 106, 583-591.

348 Katsoyiannis, A., Samara, C., 2007. Ecotoxicological evaluation of the wastewater treatment
349 process of the sewage treatment plant of Thessaloniki, Greece. J. Hazard. Mater. 141, 614-621.

350 Klüver, N., Vogs, C., Altenburger, R., Escher, B.I., Scholz, S., 2016. Development of a general
351 baseline toxicity QSAR model for the fish embryo acute toxicity test. Chemosphere 164, 164-173.

352 Kohanski, M.A., Dwyer, D.J., Collins, J.J., 2010. How antibiotics kill bacteria: from targets to
353 networks. Nature Rev. Microbiol. 8, 423-435.

354 Kolpin, D.W., Furlong, E.T., Meyer, M.T., Thurman, E.M., Zaugg, S.D., Barber, L.B., Buxton,
355 H.T., 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams,
356 1999-2000: A national reconnaissance. Environ. Sci. Technol. 36, 1202-1211.

357 Kummerer, K., 2009. Antibiotics in the aquatic environment - A review - Part I. Chemosphere 75,
358 417-434.

359 Loos, R., Carvalho, R., Antonio, D.C., Cornero, S., Locoro, G., Tavazzi, S., Paracchini, B., Ghiani,
360 M., Lettieri, T., Blaha, L., Jarosova, B., Voorspoels, S., Servaes, K., Haglund, P., Fick, J., Lindberg,
361 R.H., Schwesig, D., Gawlik, B.M., 2013. EU-wide monitoring survey on emerging polar organic
362 contaminants in wastewater treatment plant effluents. Water Res. 47, 6475-6487.

363 Neale, P.A., Ait-Aissa, S., Brack, W., Creusot, N., Denison, M.S., Deutschmann, B., Hilscherova,
364 K., Hollert, H., Krauss, M., Novak, J., Schulze, T., Seiler, T.B., Serra, H., Shao, Y., Escher, B.I.,

365 2015. Linking *in vitro* effects and detected organic micropollutants in surface water using mixture-
366 toxicity modeling. Environ. Sci. Technol. 49, 14614-14624.

367 Neuwoehner, J., Fenner, K., Escher, B.I., 2009. Physiological modes of action of fluoxetine and its
368 human metabolites in algae. Environ. Sci. Technol. 43, 6830-6837.

369 Parvez, S., Venkataraman, C., Mukherji, S., 2006. A review on advantages of implementing
370 luminescence inhibition test (*Vibrio fischeri*) for acute toxicity prediction of chemicals. Environ.
371 Int. 32, 265-268.

372 Ra, J.S., Lee, B.C., Chang, N.I., Kim, S.D., 2006. Estimating the combined toxicity by two-step
373 prediction model on the complicated chemical mixtures from wastewater treatment plant effluents.
374 Environ. Toxicol. Chem. 25, 2107-2113.

375 Schultz, T.W., Cronin, M.T.D., 1997. Quantitative structure - activity relationships for weak acid
376 respiratory uncouplers to *Vibrio fischeri*. Environ. Toxicol. Chem. 16, 357-360.

377 Tang, J.Y.M., Escher, B.I., 2014. Realistic environmental mixtures of micropollutants in surface,
378 drinking, and recycled water: Herbicides dominate the mixture toxicity towards algae. Environ.
379 Toxicol. Chem. 33, 1427-1436.

380 Tang, J.Y.M., McCarty, S., Glenn, E., Neale, P.A., Warne, M.S.J., Escher, B.I., 2013. Mixture
381 effects of organic micropollutants present in water: Towards the development of effect-based water
382 quality trigger values for baseline toxicity. Water Res. 47, 3300-3314.

383 Thomulka, K.W., McGee, D.J., Lange, J.H., 1993. Detection of biohazardous materials in water by
384 measuring bioluminescence reduction with the marine organism *Vibrio harveyi*. J. Environ. Sci.
385 Health A Tox. Hazard. Subst. Environ. Eng. 28, 2153-2166.

386 US EPA, 2008. Estimation Programs Interface Suite for Windows, v4.1., United States
387 Environmental Protection Agency, Washington, DC, USA.

388 Vaes, W.H.J., Ramos, E.U., Hamwijk, C., van Holsteijn, I., Blaauboer, B.J., Seinen, W., Verhaar,
389 H.J.M., Hermens, J.L.M., 1997. Solid phase microextraction as a tool to determine membrane/water
390 partition coefficients and bioavailable concentrations in *in vitro* systems. Chem. Res. Toxicol. 10,
391 1067-1072.

392 van de Merwe, J.P., Leusch, F.D.L., 2015. A sensitive and high throughput bacterial luminescence
393 assay for assessing aquatic toxicity - the BLT-Screen. Env. Sci. Process. Impacts 17, 947-955.

394 van der Grinten, E., Pikkemaat, M.G., van den Brandhof, E.J., Stroomberg, G.J., Kraak, M.H.S.,
395 2010. Comparing the sensitivity of algal, cyanobacterial and bacterial bioassays to different groups
396 of antibiotics. Chemosphere 80, 1-6.

397 Vethaak, A.D., Hamers, T., Martínez-Gómez, C., Kamstra, J.H., de Weert, J., Leonards, P.E.G.,
398 Smedes, F., 2016. Toxicity profiling of marine surface sediments: A case study using rapid
399 screening bioassays of exhaustive total extracts, elutriates and passive sampler extracts. Mar.
400 Environ. Res. In Press, doi:10.1016/j.marenvres.2016.03.002.

401 Watkinson, A.J., Murby, E.J., Kolpin, D.W., Costanzo, S.D., 2009. The occurrence of antibiotics in
402 an urban watershed: From wastewater to drinking water. Sci. Total Environ, 407, 2711-2723.

403 Zou, X.M., Lin, Z.F., Deng, Z.Q., Yin, D.Q., Zhang, Y.L., 2012. The joint effects of sulfonamides
404 and their potentiator on *Photobacterium phosphoreum*: Differences between the acute and chronic
405 mixture toxicity mechanisms. Chemosphere 86, 30-35.

406

407

408 **Table 1:** Selected properties of the studied non-antibiotic pharmaceuticals and antibiotics.

Chemical	CAS No	Molecular	Methanol	Log K _{ow} ^a	Log K _{lipw} ^b	Log D _{lipw} (pH 4)
		weight (g/mol)	stock solution (M)			
Carbamazepine	298-46-4	236.27	0.10	2.45	2.57	2.57 ^c
Diclofenac	15307-86-5	318.13	0.10	4.51	4.67	4.45 ^d
Fluoxetine	56296-78-7	345.79	0.05	4.05	4.20	3.84 ^{e*}
Gemfibrozil	25812-30-0	250.33	0.10	4.77	4.94	4.83 ^c
Naproxen	22204-53-1	230.26	0.01	3.18	3.31	3.21 ^c
Doxycycline	24390-14-5	512.94	0.01	-0.02	0.05	0.01 ^c
Monensin	22373-78-0	692.85	0.01	1.62	1.72	1.56 ^c
Sulfamethizole	144-82-1	270.33	0.05	0.54	0.62	0.62 ^c
Sulfamethoxazole	723-46-6	253.28	0.01	0.89	0.98	0.98 ^c
Tetracycline	64-75-5	482.92	0.01	-1.30	-1.26	-1.33 ^c

409 ^aUS EPA (2008); ^bCalculated based on Vaes et al. (1997); ^cCalculated based on Escher et al. (2011); ^dAvdeef
410 et al. (1998); ^eNeuwoehner et al. (2009)

411 ^{*}D_{lipw} measured at pH 7, but fluoxetine speciation is fully charged at pH 4 and 7.

412 **Table 2:** The fraction of each chemical used in the different equipotent mixtures.

	Non-antibiotic pharmaceutical t=0.5	Non- antibiotic pharmaceutical t=16	Antibiotic t=0.5	Antibiotic t=16	All t=0.5	All t=16
Carbamazepine	48.6%	66.1%			38.5%	64.6%
Diclofenac	2.2%	2.1%			1.8%	2.0%
Fluoxetine	35.7%	27.2%			28.5%	26.5%
Gemfibrozil	12.8%	4.4%			10.2%	4.2%
Naproxen	0.6%	0.3%			0.5%	0.3%
Doxycycline			10.1%	0.1%	2.1%	0.003%
Monensin			8.5%	4.4%	1.8%	0.1%
Sulfamethizole			26.3%	55.8%	5.4%	1.3%
Sulfamethoxazole			41.8%	39.3%	8.6%	0.9%
Tetracycline			13.4%	0.4%	2.7%	0.01%

414 **Table 3:** Experimental log EC₅₀ (M) and slope of individual chemicals at 0.5 and 16 h ± standard error (SE), with the 0.5 h to 16 h ratio.

Chemicals		t=0.5		t=16		t=0.5/t=16 ratio	Classification
		<i>log EC₅₀ ± SE</i>	<i>slope ± SE</i>	<i>log EC₅₀ ± SE</i>	<i>slope ± SE</i>		
Non-antibiotic pharmaceuticals	Carbamazepine	-3.68 ± 0.02	0.97 ± 0.05	-3.67 ± 0.05	1.82 ± 0.30	0.99	Baseline toxicant
	Diclofenac	-4.92 ± 0.01	6.35 ± 0.59	-5.24 ± 0.08	6.00 ± 0.60*	2.11	Baseline toxicant
	Fluoxetine	-3.71 ± 0.02	1.84 ± 0.14	-4.02 ± 0.03	2.54 ± 0.52	2.04	Baseline toxicant
	Gemfibrozil	-4.16 ± 0.01	2.64 ± 0.20	-4.81 ± 0.03	2.22 ± 0.20	4.43	Baseline toxicant
	Naproxen	-5.47 ± 0.02	1.49 ± 0.10	-6.03 ± 0.02	1.95 ± 0.15	3.58	Baseline toxicant
Antibiotics	Doxycycline	-4.92 ± 0.10	0.39 ± 0.04	-7.92 ± 0.02	1.42 ± 0.09	995	Specifically acting
	Monensin	-4.93 ± 0.02	1.74 ± 0.15	-6.44 ± 0.05	1.17 ± 0.13	32.6	Specifically acting
	Sulfamethizole	-4.44 ± 0.03	1.33 ± 0.09	-5.29 ± 0.03	2.48 ± 0.35	7.16	Specifically acting
	Sulfamethoxazole	-4.24 ± 0.02	1.35 ± 0.08	-5.46 ± 0.02	1.16 ± 0.06	16.7	Specifically acting
	Tetracycline	-4.83 ± 0.08	0.48 ± 0.05	-7.51 ± 0.02	1.62 ± 0.16	484	Specifically acting

415 *slope fitted to 6

Table 4: Experimental EC₅₀ (M) with 95% confidence intervals for all mixtures compared to concentration addition and independent action predictions.

	Concentration addition		Independent action (IA)		Experimental		#
	(CA) predictions		predictions				Components
	log EC ₅₀	EC ₅₀	log EC ₅₀	EC ₅₀	log EC ₅₀	EC ₅₀	
Non-antibiotic pharmaceuticals							
t=0.5	-3.99	1.03×10 ⁻⁴	-3.76	1.76×10 ⁻⁴	-4.07	8.55×10 ⁻⁵	5
	(-4.00 to	(9.91×10 ⁻⁵ to	(-3.78 to	(1.68×10 ⁻⁴ to	(-4.11 to	(7.73×10 ⁻⁵ to	
	-3.97)	1.07×10 ⁻⁴)	-3.74)	1.84×10 ⁻⁴)	-4.02)	9.47×10 ⁻⁵)	
t=16	-4.18	6.59×10 ⁻⁵	-3.82	1.52×10 ⁻⁴	-4.08	8.29×10 ⁻⁵	5
	(-4.23 to	(5.91×10 ⁻⁵ to	(-3.90 to	(1.27×10 ⁻⁴ to	(-4.13 to	(7.38×10 ⁻⁵ to	
	-4.13)	7.35×10 ⁻⁵)	-3.74)	1.82×10 ⁻⁴)	-4.03)	9.32×10 ⁻⁵)	
Antibiotics							
t=0.5	-4.59	2.56×10 ⁻⁵	-4.96	1.10×10 ⁻⁵	-4.54	2.86×10 ⁻⁵	5
	(-4.65 to	(2.23×10 ⁻⁵ to	(-5.06 to	(8.73×10 ⁻⁶ to	(-4.61 to	(2.43×10 ⁻⁵ to	
	-4.53)	2.94×10 ⁻⁵)	-5.86)	1.38×10 ⁻⁵)	-4.47)	3.36×10 ⁻⁵)	
t=16	-5.76	1.72×10 ⁻⁶	-5.64	2.27×10 ⁻⁶	-5.62	2.40×10 ⁻⁶	5
	(-5.79 to	(1.61×10 ⁻⁶ to	(-5.67 to	(2.12×10 ⁻⁶ to	(-5.71 to	(1.93×10 ⁻⁶ to	
	-5.74)	1.83×10 ⁻⁶)	-5.61)	2.43×10 ⁻⁶)	-5.53)	2.98×10 ⁻⁶)	
All components							
t=0.5	-4.20	6.36×10 ⁻⁵	-4.40	4.03×10 ⁻⁵	-4.41	3.87×10 ⁻⁵	10
	(-4.27 to	(5.38×10 ⁻⁵ to	(-4.51 to	(3.11×10 ⁻⁵ to	(-4.48 to	(3.33×10 ⁻⁵ to	
	-4.12)	7.51×10 ⁻⁵)	-4.28)	5.22×10 ⁻⁵)	-4.35)	4.49×10 ⁻⁵)	
t=16	-4.46	3.50×10 ⁻⁵	-4.11	7.85×10 ⁻⁵	-4.28	5.29×10 ⁻⁵	10
	(-4.50 to	(3.19×10 ⁻⁵ to	(-4.16 to	(6.87×10 ⁻⁵ to	(-4.32 to	(4.84×10 ⁻⁵ to	
	-4.41)	3.85×10 ⁻⁵)	-4.05)	8.97×10 ⁻⁵)	-4.24)	5.79×10 ⁻⁵)	
Two-step prediction (TSP)							
	log EC ₅₀		EC ₅₀		Experimental		
t=0.5			5.34×10 ⁻⁵		-4.41	3.87×10 ⁻⁵	10
	-4.27 (-4.29 to -4.26)		(5.16×10 ⁻⁵ to 5.52×10 ⁻⁵)		(-4.48 to	(3.33×10 ⁻⁵ to	
					-4.35)	4.49×10 ⁻⁵)	
t=16			4.40×10 ⁻⁵		-4.28	5.29×10 ⁻⁵	10
	-4.36 (-4.36 to -4.36)		(4.38×10 ⁻⁵ to 4.41×10 ⁻⁵)		(-4.32 to	(4.84×10 ⁻⁵ to	
					-4.24)	5.79×10 ⁻⁵)	

NB: 95% confidence intervals were calculated based on the derived σlogEC from error propagation.

419 **List of Figures**

420

421 **Figure 1:** Concentration-effect curves for non-antibiotic pharmaceuticals and antibiotics at 0.5 and
422 16 h.

423

424 **Figure 2:** log EC₅₀ at 0.5 h versus log EC₅₀ at 16 h.

425

426 **Figure 3:** Experimental EC₅₀ values in the BLT-Screen at 0.5 h (closed black symbols) and 16 h
427 (open black symbols) (pH 4) compared to literature BLT-Screen (0.5 h) EC₅₀ values for
428 carbamazepine, gemfibrozil and naproxen (blue closed diamond) (pH 4) (van de Merwe and
429 Leusch, 2015) and literature Microtox EC₅₀ values for diclofenac, fluoxetine, gemfibrozil,
430 naproxen, doxycycline, sulfamethoxazole and tetracycline (red closed triangle) (pH 7) (Tang et al.,
431 2013). The experimental EC₅₀ values in the present study were also compared to the baseline
432 toxicity QSAR predictions (red line) from Tang et al. (2013), which were corrected for speciation
433 using log D_{lipw} at pH 4.

434

435 **Figure 4:** Concentration addition (CA) and independent action (IA) predictions for the five-
436 component non-antibiotic pharmaceutical mixtures at A) 0.5 h and B) 16 h and the five-component
437 antibiotics mixtures at C) 0.5 h and D) 16 h, with CA, IA and two-step prediction (TSP) for the ten-
438 component non-antibiotic pharmaceutical and antibiotics mixtures at E) 0.5 h and F) 16 h.
439 Experimental results are shown using white squares. Different mixture ratios were used for each
440 time point and are provided in Table 2.

441

447 **Figure 2**

448
449

450 **Figure 3**

451
452
453
454
455

457

458